CVVT

Last week, the global healthcare community gathered in Hong Kong for the prestigious 6th Asia Summit on Global Health (ASGH) 2026. Jointly organised by the HKSAR Government and the Hong Kong Trade Development Council (HKTDC), the summit operated under the theme "Fuelling Healthcare Breakthroughs". As a leader in medical innovation, CVVT was proud to play a role in this flagship event, which drew 3,000 participants from 43 countries to explore the future of the global healthcare ecosystem. ...

In the press conference of 12 February 2026, Professor KY Yuen in his capacity as the Director of the Centre of Virology, Vaccinology and Therapeutics (CVVT) delivered an academic talk about a novel scientific approach which leads to the discovery of compounds or extracts which inhibit the release of toxin by Staphylococcus aureus without killing the bacteria. This approach would reduce the risk of induction of antibiotic resistance and disruption of the normal microbiome of human. Prof Yuen...

新聞稿 即時發佈 【中國香港— 2026年3月31日】 — 比幹生物有限公司（比幹生物）、InnoHK 病毒與疫苗研究中心（CVVT）、深圳華大智造科技股份有限公司（華大智造）以及臨床腫瘤學合作夥伴鄺麗雲教授今日宣布策略性合作，並成立 PDOHub™ HK ，即 亞洲首個整合式類器官精準醫學中心 。這項策略性合作結合前沿類器官技術、自動化系統及臨床專業知識，旨在加速精準醫學發展、輔助臨床決策，並推動腫瘤學及傳染病領域的轉化研究。 亞洲首個整合式 PDOHub™ HK 該策略性合作協議體現各方共同致力於建立及發展一個專注於患者來源類器官（PDO）技術的中心，以推進多個疾病領域的精準醫學、臨床決策及轉化研究。PDOHub™ HK（以下簡稱 PDOHub）將作為開發及擴展類器官應用技術的核心樞紐，連接前沿科學與臨床實踐。透過提供患者個性化的深度見解，該計劃賦能研究人員和醫療合作夥伴，加速在傳染病、腫瘤和其他新興健康挑戰領域的發現並完善治療策略，從而使PDOHub成為亞洲領先的類器官驅動型精準醫療中心。 近十年類器官科研為 PDOHub™ HK 奠定基礎...